Papillary Carcinoma

Subscribe to Selected New Research on Papillary Carcinoma

1226 relevant articles (18 outcomes, 113 trials/studies) found for this Disease

Description: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)

Also Known As:

Carcinoma, Papillary; Carcinomas, Papillary; Papillary Carcinomas

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Histologic Type: 1

Glandular and Epithelial Neoplasms: 252

Carcinoma: 92356

Papillary Carcinoma: 1226

Squamous Cell Neoplasms: 776

Papillary Carcinoma: 1226

Related Diseases

1.	Carcinoma (Carcinomatosis)
2.	Neoplasms (Cancer)
3.	Adenoma (Adenomas)
4.	Thyroid Neoplasms (Thyroid Cancer)
5.	Thyroiditis

Experts

1.	Scarpino, S: 3 articles (08/2007 - 03/2000)
2.	Fusco, Alfredo: 2 articles (09/2007 - 06/2002)
3.	Palmieri, Michela: 2 articles (04/2007 - 05/2006)
4.	Pecorelli, Sergio: 2 articles (04/2007 - 05/2006)
5.	Bandiera, Elisabetta: 2 articles (04/2007 - 05/2006)
6.	Santin, Alessandro D: 2 articles (04/2007 - 05/2006)
7.	Bellone, Stefania: 2 articles (04/2007 - 05/2006)
8.	Marizzoni, Moira: 2 articles (04/2007 - 05/2006)
9.	Chiappetta, G: 2 articles (06/2006 - 06/2000)
10.	Santoro, M: 2 articles (06/2006 - 06/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Papillary Carcinoma:

1.	ParaffinIBA 02/01/2002 - "Histological examination of the operative specimen after total blocking in paraffin helped discover microscopic foci of papillary carcinoma in the thyroid gland. " 10/25/2006 - "METHODS: Immunohistochemical staining for CD57 and GLUT-1 was performed on paraffin-embedded cell blocks of 50 thyroid FNA cases with the following cytologic diagnoses: 1) papillary carcinoma (15 cases); 2) atypical cytology, cannot exclude papillary carcinoma (14 cases); and 3) benign thyroid (21 cases). " 12/01/2005 - "Of 10 serous papillary carcinomas, 8 (80%) for which paraffin blocks were available overexpressed the p53 protein. " 10/31/2004 - "Seventy paraffin-embedded conventional papillary carcinomas in the thyroid gland were evaluated. " 08/01/2000 - "Fresh-frozen and paraffin-embedded papillary carcinomas from 27 New Caledonian and 20 Australian patients were examined for ret rearrangements by means of RT-PCR with primers flanking the chimeric region, followed by hybridization with radioactive probes. " Order ALL the reference details at left...
2.	IodineIBA 04/01/2009 - "Most studies attribute this rise entirely to the increase in papillary carcinoma, the most common thyroid malignancy in iodine-sufficient areas. " 11/01/2009 - "Extensive papillary carcinoma of the thyroid gland treated by external beam radiotherapy, surgery and postoperative radioactive iodine therapy." 07/01/2007 - "This may be related to increasing dietary iodine intake and may be significant as papillary carcinoma is associated with a more favourable prognosis." 07/01/2002 - "Patients who were born in iodine-sufficient areas (n=162/193, 84%; X(2)=5.09, P=0.02) had papillary carcinoma more frequently compared to patients who were born in previously iodine-deficient areas (n=159/214, 74%). " 12/01/2000 - "Because of reported aggressive behaviour of familial papillary carcinoma of the thyroid, aggressive surgical treatment plus post-operative thyroid remnant ablation with radio-iodine should be warranted in all patients." Order ALL the reference details at left...
3.	Galectin 3 (LGALS3)IBA 07/01/2006 - "Our study shows that galectin-3 is strongly expressed in smears of papillary carcinoma. " 12/01/2008 - "Five cases of six papillary carcinomas had positive staining for Galectin-3, while one case (the case with a papillary microcarcinoma) had not. " 11/21/2008 - "Accordingly, relative galectin-3 value allows a definitive diagnosis of papillary carcinoma independent of cellular morphology, whereas serum galectin-3 does not serve as a marker for papillary carcinoma." 11/21/2008 - "Relative galectin-3 value (ng/mg), defined as galectin-3 concentration (ng/ml) divided by total protein concentration (mg/ml) in fine needle aspirates, was significantly higher in papillary carcinoma than in the other thyroid entities. " 06/01/2008 - "CONCLUSIONS: Galectin-3 appears to be a useful marker in the diagnosis of papillary carcinoma only. " Order ALL the reference details at left...
4.	AntibodiesIBA 10/01/1985 - "SOM-positive cells were identified in six cases and a-hCG or 5-HT-positive cells respectively in three cases of group III. Twenty follicular and 20 papillary carcinomas also included in this study did not react with any of the above mentioned antibodies. " 09/01/2006 - "MATERIAL AND METHOD: One hundred and one cases of papillary carcinomas were studied with immunohistochemistry for RET antibodies. " 11/01/1999 - "Four of the cases of papillary carcinoma were also stained with antibodies to CK19. " 01/01/1986 - "Phosphofructokinase from papillary carcinomas show a lesser degree of precipitation with anti-M antibodies. " 11/01/2003 - "Indirect immunofluorescence using anti-EBNA2, anti-latent membrane protein-1 (LMP1), and anti-BZLF1 antibodies also showed positive results with high frequency and with more prominent fluorescence in undifferentiated carcinomas than in papillary carcinomas. " Order ALL the reference details at left...
5.	DNA (Deoxyribonucleic Acid)IBA 02/01/2007 - "DNA ploidy studies were carried out on 28 low-grade and 21 high-grade papillary carcinomas. " 01/01/1991 - "DNA-analysis is well established in our clinical work and is one of the factors considered in a prospective randomized study concerning patients with papillary carcinoma in the Stockholm-Uppsala area. " 03/01/1982 - "Chromosome and DNA cytometric study of a papillary carcinoma of the bladder with a high stemline and numerous double minutes." 02/01/2007 - "The present findings establish that the DNA content is statistically different between low-grade and high-grade papillary carcinomas and that deviation from the diploid number is markedly higher in the high-grade ones. " 05/01/2005 - "The results indicate that despite the similar average distance between the AT- and the GC-rich DNA segments in the papillary carcinomas and the benign cases, the former has more heterogeneous distribution of the AT- and the GC-rich DNA segments in nuclei compared to the benign groups. " Order ALL the reference details at left...
6.	Thyroxine (Levothyroxine)FDA LinkGeneric 12/01/1994 - "In papillary carcinoma thyroxine administration (P < 0.005) and surgery (P < 0.001) improved survival together with youth (P < 0.001) and being female (P < 0.05). " 12/01/2003 - "A woman, thyroidectomised because of a thyroid papillary carcinoma, interrupted temporarily her levothyroxine intake in order to be subjected to an extension study five weeks later. " 01/01/1983 - "Furthermore, in three cases of papillary carcinoma the concentration of free thyroxin was increased, although all the other laboratory tests indicated a euthyroid state. " 11/01/1993 - "We underline the case of a patient, treated by total thyroidectomy for papillary carcinoma, who presented, two months after starting L-thyroxine therapy, a recurrence of celiac disease, that had been silent after childhood. " 07/01/2003 - "CONCLUSIONS: Base upon our past and current experience,we recommend that thyroglossal duct cyst with a microscopic focus of papillary carcinoma without cyst wall invasion be managed with Sistrunk procedure along with effective suppressant dose of thyroxine." Order ALL the reference details at left...
7.	LectinsIBA 08/01/1986 - "In papillary carcinomas, the cells lining the papillary structures reacted focally with some lectins that did not bind to normal thyroid cells (S tuberosum and U europeaus in seven of seven cases; Helix pomatia, Helix aspersa, and soybean in four of seven cases; and peanut, Griffonia simplicifolia, D biflorus, and Vicia villosa in one of seven cases). " 12/01/1988 - "The results showed that (1) in normal thyroid glands, the lectin, UEA-I, is able to discriminate between follicular cells and C-cells; (2) pathologic follicular epithelium had an increased expression of UEA-I, SBA, and WGA receptors; (3) no lectin or group of lectins allow a distinction between follicular carcinoma and papillary carcinoma; (4) when benign and malignant tumors are compared for UEA-I affinity there is a significantly greater frequency of malignant tumour with UEA-I receptor; and (5) although all investigated lectins have shown receptors in endothelial cells at least in one case, the most constant findings have been obtained with UEA-I and WGA. " 12/01/1988 - "The authors carried out a histochemical study with lectins (Ulex europaeus agglutinin-I [UEA-I], Triticum vulgaris [WGA], Glycine max [SBA], Dolichos biflorus [DBA], and Arachis hypogaea [PNA]) in different thyroid gland conditions (17 benign nodular goiters, three diffuse hyperplasias, five Hashimoto's thyroiditis, 20 follicular adenomas, 14 well-differentiated papillary carcinomas, five well-differentiated follicular carcinomas, and 30 normal thyroids) in order to determine if specific lectin patterns are developed during neoplastic transformation. " 01/01/1996 - "Staining with lectins specific to poly-N-acetyllactosamine in combination with endo-beta-galactosidase digestion demonstrated that poly-N-acetyllactosaminyl structures ubiquitously and consistently produced in thyroid papillary carcinomas are highly heterogeneous in their chain length and branching status and quite different from those produced in other thyroid neoplasms. " Order ALL the reference details at left...
8.	Keratin-19 (Keratin 19)IBA 03/01/2008 - "Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction." 05/01/2003 - "CONCLUSIONS: Cytokeratin 19 immunostaining of cell block preparations of thyroid aspirates serves as a useful tool for the diagnosis of papillary carcinoma. " 11/01/1989 - "In papillary carcinoma, an identical homogeneous expression of keratin 19 was observed in both papillary and follicular structures, which suggests a common cellular origin. " 01/01/2005 - "The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease." 05/01/2003 - "CONTEXT: Immunohistochemical staining for cytokeratin 19 (CK-19) is a useful ancillary technique for diagnosing papillary thyroid carcinoma (papillary carcinoma) in histologic specimens. " Order ALL the reference details at left...
9.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/01/1996 - "Tumor necrosis factor-alpha was demonstrated in thyroid follicular epithelial cells, most frequently in non-toxic multinodular goiters (six of seven patients) and less frequently in adenomas (three of nine patients), papillary carcinomas (two of five patients), follicular carcinomas (one of five patients), Hashimoto's disease (one of six patients) and Grave's disease (one of seven patients). " 04/01/1992 - "In a fifth neoplastic cell line (papillary carcinoma, NPA) that constitutively expressed surface DR, its expression was inhibited by both alpha-IFN and TNF-alpha and was not affected by EGF." 06/01/1995 - "Compared with follicular carcinomas, papillary carcinomas contained significantly higher numbers of DCs, interleukin (IL)-1 alpha- and tumor necrosis factor (TNF)-alpha-positive cells, and cells positive for two TNF-alpha receptors (p60 and p80). " 07/13/2000 - "The efficacy of TRAIL was also tested on other types of thyroid cancer cells like ARO, FRO (anaplastic carcinoma) and TPC-1 (papillary carcinoma) and compared to that triggered by other death inducing cytokines FasL and TNF-alpha. " 11/01/1996 - "Primary cultures of highly purified thyrocytes and thyroid-derived fibroblasts (n = 3) and three thyroid anaplastic and one largely papillary carcinoma cell lines were exposed to different potent GM-CSF stimulators, employing interleukin 1 alpha (Il-1 alpha) and tumour necrosis factor-alpha (TNF-alpha). " Order ALL the reference details at left...
10.	keratan-sulfate endo-1,4-beta-galactosidaseIBA 08/01/1995 - "Prior digestion with endo-beta-galactosidase completely eliminated or markedly reduced the reactivity with PWM and LEA in papillary carcinomas. " 09/01/1996 - "Along with the endo-beta-galactosidase-GSA-II labelling procedure, labelling with 5-D-4 may be a useful diagnostic means for distinguishing papillary carcinoma from other types of thyroid neoplasms." 08/01/1995 - "Blood-group-related antigens expressed in papillary carcinomas and other types of neoplasm of the human thyroid glands have been shown to be carried by poly-N-acetyllactosamines containing a linear domain susceptible to endo-beta-galactosidase digestion. " 02/01/1995 - "Endo-beta-galactosidase digestion resulted in the elimination of these antigens not only in papillary carcinomas but also in other neoplasms.(ABSTRACT TRUNCATED AT 250 WORDS)" 09/01/1996 - "The reactivity of 5-D-4 with papillary carcinomas was markedly reduced or abolished by prior digestion with endo-beta-galactosidase, keratanase II, or N-glycosidase F. " Order ALL the reference details at left...

Therapies and Procedures

1.	Thyroidectomy 05/01/2005 - "CONCLUSIONS: The preliminary results of this study showed that non endoscopic minimally invasive thyroidectomy could be proposed in patients with T1 papillary carcinoma. " 06/01/1997 - "STUDY DESIGN: To define the roles of fine-needle aspiration and frozen section in papillary carcinoma of the thyroid gland, we reviewed data from 82 patients who underwent thyroidectomy between August 1989 and August 1995 for papillary carcinoma of the thyroid cytology. " 08/01/1995 - "The objective of the study was to assess surgical strategy of papillary carcinoma of the thyroid based on residual tumour findings after completion thyroidectomy. " 08/01/1993 - "Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extension to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resection." 04/01/1990 - "The results of this study suggest that the surgical approach in papillary carcinoma of the thyroid is total thyroidectomy because reoperation were performed in four patients." Order ALL the reference details at left...
2.	Neck Dissection (Radical Neck Dissection) 04/01/2009 - "OBJECTIVE: Prophylactic neck dissection for small papillary carcinoma remains controversial. " 03/01/2008 - "METHODS: Thirty-seven patients with papillary carcinoma of the thyroid and evidence of positive adenopathy at levels II-V underwent selective neck dissection and elective/therapeutic paratracheal neck dissection. " 03/01/2008 - "BACKGROUND: Therapeutic paratracheal neck dissection for patients with papillary carcinoma of the thyroid is standard treatment. " 02/01/2007 - "Furthermore, small foci of metastatic papillary carcinoma were identified in two ipsilateral lymph nodes from neck dissection specimen. " 01/01/2005 - "The author analyses a group of 2917 patients with papillary carcinoma of the thyroid gland, on 2210 of them (75.5%) a modified neck dissection was performed, 268 (9.2%) underwent central lymphodissection, in 449 (15.3%) the lymph nodes were not ablated. " Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 07/01/2009 - "CONCLUSION: scFv H6 may represent a novel antitumor agent against chemotherapy-resistant ovarian and serous papillary carcinomas and other human malignancies that overexpress CLDN3." 11/01/2006 - "In addition, one case of thyroid papillary carcinoma located at neck-root and mediastinum remained alive for 40 months after operation combined with radiotherapy and chemotherapy. " 06/01/1979 - "The second case is a papillary carcinoma and associated microacinar type with the papillary component responding dramatically to chemotherapy. " 10/01/1966 - "Intracavitary chemotherapy of diffuse non-infiltrating papillary carcinoma of the bladder." 06/01/2006 - "Chemotherapy is active against both endometrioid-type carcinoma and uterine serous papillary carcinoma. " Order ALL the reference details at left...
4.	Lymph Node Excision (Lymph Node Dissection) 11/02/2000 - "For N-staging selective lymphadenectomy was carried out at the beginning of the study, but elective lymphadenectomy was used since 1996 for papillary carcinoma. " 08/01/1986 - "[Study on extensive lymph node dissection: metastatic lymph nodes in papillary carcinoma of the thyroid]" 03/15/2009 - "The role of lymphadenectomy in the management of papillary carcinoma of the thyroid." 02/01/2009 - "Omentectomy and paraaortic lymphadenectomy were also performed for women with clear cell or serous papillary carcinoma (5 patients). " 12/01/2006 - "For small papillary carcinomas of 2.0 cm or less (T1), thyroid resection was more extensive in foreign countries than in Japan, although the extent of lymph node dissection was limited in the former. " Order ALL the reference details at left...
5.	Intravesical Administration 04/01/1993 - "A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder." 01/01/1993 - "We compared intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM in patients with pTa-pT1 papillary carcinoma and primary carcinoma in situ (CIS) of the bladder. " 08/01/2001 - "Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Papillary Carcinoma

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>